Generics· July 2, 2026 · 18 min read
Why Generic Jardiance Has Not Launched: Empagliflozin Patent Cliff
By Ran Chen#Generic Entry#Orange Book#SGLT2 Inhibitor
Section
Generics
ANDA strategy, Orange Book records, therapeutic equivalence, exclusivity, and price erosion.
29 articles · Last updated
Generics· June 29, 2026 · 18 min read
Generic Xarelto Entry: Orange Book Patents and NADAC Price Erosion
By Ran Chen#Generics#Orange Book#Generic Entry
Generics· June 27, 2026 · 18 min read
Generic Aubagio Market: ANDA Litigation Settlements and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Market Access
Generics· June 27, 2026 · 17 min read
Generic Latuda Market: ANDA Exclusivity Settlements and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Market Access
Generics· June 27, 2026 · 18 min read
Generic Restasis: Complex Ophthalmic Barriers and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Ophthalmology
Generics· June 26, 2026 · 22 min read
Generic Revlimid REMS Launch: Lenalidomide ANDA Entry and NADAC Absence
By Ran Chen#Generics#Orange Book#Oncology
Generics· June 26, 2026 · 21 min read
Generic Tecfidera: Dimethyl Fumarate Patent Settlements and NADAC Erosion
By Ran Chen#Generics#Orange Book#PBM
Generics· June 26, 2026 · 21 min read
Generic Zytiga: Abiraterone Acetate ANDA Saturation and NADAC Pricing
By Ran Chen#Generics#Orange Book#Oncology
Generics· June 25, 2026 · 19 min read
Generic Copaxone: FDA Guidance and NADAC Pricing Dynamics
By Ran Chen#Generics#Orange Book#FDA Approval
Generics· June 25, 2026 · 19 min read
Generic Forteo: Drug-Device Pathways and PBM Exclusions
By Ran Chen#Generics#Orange Book#505(b)(2)